TEL AVIV, Israel & MELBOURNE, Australia
Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site from November 23 to December 3.
Azura will be participating in 1×1 meetings on Monday, November 30. Meetings may be requested exclusively via Piper Sandler.
About Azura Ophthalmics, Ltd.
Azura Ophthalmics is a clinical-stage company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S. The company is developing an innovative portfolio of compounds to advance treatments for Meibomian gland dysfunction (MGD), the leading cause of Dry Eye Disease (DED). By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatment options are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. For more information visit: www.azuraophthalmics.com and follow Azura on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201123006279/en/
CONTACT
Health+Commerce
Hannah Boxerman
707.326.0870
hannah@healthandcommerce.com
